222 related articles for article (PubMed ID: 23363399)
1. Recent developments of DNA poisons--human DNA topoisomerase IIα inhibitors--as anticancer agents.
Pogorelčnik B; Perdih A; Solmajer T
Curr Pharm Des; 2013; 19(13):2474-88. PubMed ID: 23363399
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents.
Pogorelčnik B; Perdih A; Solmajer T
Curr Med Chem; 2013; 20(5):694-709. PubMed ID: 23210851
[TBL] [Abstract][Full Text] [Related]
3. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
Bergant K; Janezic M; Perdih A
Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
[TBL] [Abstract][Full Text] [Related]
4. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα.
Bergant K; Janežič M; Valjavec K; Sosič I; Pajk S; Štampar M; Žegura B; Gobec S; Filipič M; Perdih A
Eur J Med Chem; 2019 Aug; 175():330-348. PubMed ID: 31096154
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
9. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
10. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.
Pogorelčnik B; Janežič M; Sosič I; Gobec S; Solmajer T; Perdih A
Bioorg Med Chem; 2015 Aug; 23(15):4218-4229. PubMed ID: 26183545
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
Han X; Zhong Y; Zhou G; Qi H; Li S; Ding Q; Liu Z; Song Y; Qiao X
Bioorg Med Chem; 2017 Jun; 25(12):3116-3126. PubMed ID: 28462840
[TBL] [Abstract][Full Text] [Related]
12. Discovery of mono- and disubstituted 1H-pyrazolo[3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase IIα.
Pogorelčnik B; Brvar M; Žegura B; Filipič M; Solmajer T; Perdih A
ChemMedChem; 2015 Feb; 10(2):345-59. PubMed ID: 25522133
[TBL] [Abstract][Full Text] [Related]
13. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679
[TBL] [Abstract][Full Text] [Related]
14. D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα.
Gui M; Shi DK; Huang M; Zhao Y; Sun QM; Zhang J; Chen Q; Feng JM; Liu CH; Li M; Li YX; Geng M; Ding J
Invest New Drugs; 2011 Oct; 29(5):800-10. PubMed ID: 20336347
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
16. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
[TBL] [Abstract][Full Text] [Related]
17. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.
Vann KR; Ergün Y; Zencir S; Oncuoglu S; Osheroff N; Topcu Z
Bioorg Med Chem Lett; 2016 Apr; 26(7):1809-12. PubMed ID: 26906637
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
20. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
